Crossmark

Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes

Crossref DOI link: https://doi.org/10.1186/s13098-018-0392-8

Published Online: 2018-12-17

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Wen-qiang

Tian, Yuan

Chen, Xiao-min

Wang, Li-fen

Chen, Chan-chan

Qiu, Chuan-mei
Clinical Trials ^BETA

Clinical trials referenced in this document:

chictr1800018008 at Chinese Clinical Trial Registry

Documents that mention this clinical trial

Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes
https://doi.org/10.1186/s13098-018-0392-8
Funding

Funding for this research was provided by:

Science and Technology Benefit Fund of Xiamen Technology Bureau (3502Z20154027)
License Information

Text and Data Mining valid from 2018-12-01

Version of Record valid from 2018-12-17
More Information

Article History

Received: 5 October 2018

Accepted: 11 December 2018

First Online: 17 December 2018

Document is current

Any future updates will be listed below